Shots:
- Schrödinger to receive up front to fund the share of research costs & is also eligible to receive ~$338M in pre/ clinical, regulatory & sales-based milestones along with royalties on sales outside the US
- Zai will be responsible for the global development, manufacturing, and commercialization of the selected candidates. Schrödinger will be eligible for 50% of the profits from the commercialization of the therapy if it elects to co-fund the candidate emerges under collaboration
- Schrödinger to get co-development and co-commercialization rights in the US. Additionally, each company will be responsible for its research program expenses
Click here to read full press release/ article | Ref: Businesswire | Image: Trading View
The post Schrödinger Signs a R&D Collaboration with Zai Lab for Oncology Program Targeting DNA Damage Response first appeared on PharmaShots.
